January 03, 2014
1 min read

Anti-VEGF outperforms grid laser treatment for macular edema after BRVO

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Intravitreal ranibizumab improved and sustained vision better than grid laser treatment in eyes with macular edema secondary to branch retinal vein occlusion, according to a study.

The prospective randomized trial included 36 patients with vision loss in one eye from macular edema attributed to BRVO. A study group comprising 15 patients was randomized to receive six monthly injections of 0.5 mg Lucentis (ranibizumab, Genentech) and monthly as-needed injections. A control group of 21 patients underwent sham injections for 1 year.

Grid laser treatment was performed at 13 weeks and 25 weeks in patients in both groups who met criteria for laser treatment.

Patients in the ranibizumab group gained a mean of 12.5 letters at 12 months, and those in the sham injection group lost a mean of 1.6 letters. The between-group difference was statistically significant (P = .032). Central foveal thickness decreased significantly more in the ranibizumab group than in the sham group (P = .025).

More patients in the sham group underwent grid laser treatment than those in the treatment group.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.